Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654612 | 0.84 | DGAT1 (0.40) | AGBL2KMT2AKDM4EALDH1A1ASPH | |
| SCHEMBL29622783 | 0.84 | DGAT1 (0.40) | AGBL2KMT2AKDM4EALDH1A1ASPH | |
| SCHEMBL19899936 | 0.83 | GPR17 (0.43) | AGBL2TSHRTHRB | |
| SCHEMBL4530478 | 0.81 | AGBL2 (0.69) | AGBL2AKR1B1CYP1A2CYP2C9GABRR1 | |
| SCHEMBL29781576 | 0.81 | AGBL2 (0.69) | AGBL2AKR1B1CYP1A2CYP2C9GABRR1 | |
| SCHEMBL23273501 | 0.80 | HSP90AB1 (0.38) | AGBL2MEN1KMT2AALDH1A1 | |
| SCHEMBL29009968 | 0.80 | GPR17 (0.38) | AGBL2POLBHCAR2TSHR | |
| SCHEMBL29737883 | 0.80 | HSP90AB1 (0.38) | AGBL2MEN1KMT2AALDH1A1 | |
| SCHEMBL30979532 | 0.80 | AGBL2 (0.53) | AGBL2AKR1B1MEN1CYP1A2CYP2C9 | |
| SCHEMBL27462826 | 0.80 | AGBL2 (0.53) | AGBL2AKR1B1MEN1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335374-B | GLP-1R modulating compounds | 吉利德科学公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119874674-A | GLP-1R modulating compounds | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114630823-B | GLP-1R Modulating Compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115335374-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4048664-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021154796-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9556197-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3036238-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Corporation (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | AGBL2 1979/4885AKR1B1 3151/4885MEN1 3183/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | AGBL2 1409/4885AKR1B1 2682/4885MEN1 1966/4885 |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | PIM1, PIM2, PIM3 | AGBL2 1979/4885AKR1B1 3151/4885MEN1 3183/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | AGBL2 1004/4885AKR1B1 1767/4885MEN1 1373/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | AGBL2 1979/4885AKR1B1 3151/4885MEN1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.